NexImmune, Inc. Stock

Equities

NEXI

US65344D2080

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-06-21 pm EDT 5-day change 1st Jan Change
2.87 USD +5.90% Intraday chart for NexImmune, Inc. -2.71% +29.28%
Sales 2022 - Sales 2023 - Capitalization 2.35M
Net income 2022 -62M Net income 2023 -32M EV / Sales 2022 -
Net cash position 2022 33.62M Net cash position 2023 3.13M EV / Sales 2023 -
P/E ratio 2022
-0.09 x
P/E ratio 2023
-0.07 x
Employees 6
Yield 2022 *
-
Yield 2023
-
Free-Float 78.05%
More Fundamentals * Assessed data
Dynamic Chart
1 day+5.90%
1 week-2.71%
Current month-6.21%
1 month-13.03%
3 months-51.11%
6 months+27.56%
Current year+29.28%
More quotes
1 week
2.69
Extreme 2.69
2.96
1 month
2.65
Extreme 2.65
3.31
Current year
2.32
Extreme 2.32
28.69
1 year
1.25
Extreme 1.2501
28.69
3 years
1.25
Extreme 1.2501
469.50
5 years
1.25
Extreme 1.2501
700.00
10 years
1.25
Extreme 1.2501
700.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 17-05-31
Founder 56 11-06-06
Compliance Officer - -
Members of the board TitleAgeSince
Chairman 76 19-12-15
Director/Board Member 58 16-12-31
Director/Board Member 54 17-01-31
More insiders
Date Price Change Volume
24-06-21 2.87 +5.90% 7 073
24-06-20 2.71 -2.87% 5,393
24-06-18 2.79 -5.42% 2,269
24-06-17 2.95 0.00% 3,415
24-06-14 2.95 +1.72% 2,109

Delayed Quote Nasdaq, June 21, 2024 at 04:00 pm EDT

More quotes
NexImmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to immunotherapy designed to employ the body’s own T cells to generate an immune response that mimics natural biology. Its product candidates include NEXI-001 in acute myeloid leukemia (AML); NEXI-002 in multiple myeloma (MM), and NEXI-003, a solid tumor product candidate for Human papillomavirus (HPV) related cancers. The Company provides Artificial Immune Modulation (AIM), which is a nanoparticle technology platform. Its AIM technology enables it to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. The AIM nanoparticles employ signaling proteins to deliver instructions to T cells directing a desired immune response. The Company is also developing new AIM nanoparticle constructs and modalities for clinical evaluation in oncology and autoimmune disorders.
More about the company